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Objectives: We describe a key informant study that invited national medicines policy leads 
for the European Union member states to self-assess the level of implementation of medicines 
adherence initiatives in their country and the adequacy of that implementation. Interviews with 
medicines policy leads enabled in-depth understanding of the variation in adherence support 
across nations and the ways in which different nations prioritize, plan, and implement medicines 
adherence systems and services.
Methods: Ten national policy leads (Bulgaria, Denmark, Estonia, Finland, Germany, Ireland, 
Latvia, Lithuania, Malta, and the Netherlands) completed a self-assessment survey, and seven 
(Estonia, Finland, Germany, Ireland, Lithuania, Malta, and the Netherlands) engaged in a 
follow-up interview.
Key findings: Policy leads varied in the level of implementation of medication adherence 
solutions that they reported in their nations; most initiatives were aimed directly at patients 
with few initiatives at government or health care commissioner levels of action. Policy leads 
reported insufficient implementation of medication adherence initiatives across all potential 
domains. Barriers to implementation included lack of resources, strategic planning, evidence to 
support action, the “hidden” nature of medication adherence within policy work, and dispersed 
responsibility for medication adherence as a policy and practice theme.
Conclusion: This study has international significance and summarizes the emergent character-
istics of nations with and without coordinated medication adherence activity. We highlight the 
importance of sharing good practice in policy formulation and implementation for medication 
adherence.
Keywords: medication adherence, policy implementation, medicines policy, health care 
policy
Introduction
At any one time, 30%–50% of the European populations who are prescribed medication 
for the prevention or treatment of illness are nonadherent to that medication.1 Guidance 
exists to support health care providers and professionals deliver services that support 
medicines adherence,2 and there are many examples of current services that could be 
replicated and commissioned to support medicines adherence.3,4 Yet widespread adoption, 
commissioning, and implementation of medicines adherence support and services remain 
elusive. A challenge for health care commissioners and policymakers is deciding what can 
be commissioned and delivered in routine clinical practice and within limited budgets. 
Little is known about how policymakers and commissioners perceive the state of the art 
in medicines adherence support, the factors that influence how policymakers formulate 
relevant policies, or commissioners’ perceptions of the extent and adequacy of current 
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policy implementation to support medicines adherence. There 
have been only limited attempts to understand how health care 
policymakers and commissioners utilize research evidence in 
this area, incorporate that evidence with other priorities, and 
make decisions about the nature, level, and type of input that 
may be needed and appropriate in their locality.
Here, we present a key informant study in which poli-
cymakers self-assess policy implementation for medication 
adherence in their own nation and discuss the range of influ-
ences on their policy decision-making.
The nature of the relationship between research and 
health care policy has been conceptualized in a number of 
ways. Traditional models propose a straightforward linear, 
rational process in which research knowledge is transferred 
to policymakers. Contextual and multidimensional models 
instead propose that the reductionist approach of linear 
models simplifies the nature of the relationship between 
research and policy and fails to take account of the broader 
range of influences on policymakers, the range of stake-
holders involved in the policy influencing process, and the 
competing priorities that policymakers juggle.5–7
In addition, there are a number of specific factors in the 
medication adherence field that mitigate against a strong 
uptake of research evidence by policymakers. Research 
with policymakers demonstrates that they appreciate brevity 
and clear, simple messages, rather than academic-oriented 
publications to inform their views and actions.8 A number 
of terms, and concepts underpinning those terms, have been 
used to describe medication adherence. Multiple terms for 
similar concepts, and misuse of those terms, may hinder the 
nonspecialist policymaker from engaging with the adherence 
field and its literature. A range of theoretical and conceptual 
models have previously been used to explain the causes of 
nonadherence. Theoretical plurality benefits a burgeoning 
and growing research literature as common causes of non-
adherence across a range of illnesses and medications are 
found and exceptions to the rule are identified. However, the 
hard-pressed policymaker may find diversity in the medica-
tion adherence narrative a barrier to action: how can we fix 
the problem of nonadherence if the experts cannot agree on 
what it is and what causes it?
Elsewhere,9 we report the development of medication 
adherence policy solutions by a panel of experts belonging 
to medicines stakeholder groups who took part in an online 
Delphi study and subsequent consensus meeting. This 
resulted in 26 consensus-based policy recommendations 
deemed by the panel to be high priority for addressing medi-
cation nonadherence across Europe (Table 1). The breadth 
of the policy solutions developed by the expert panel enables 
significant flexibility in local implementation, to reflect dif-
ferences in health care systems, health-related culture, avail-
able resources, and the level and sophistication of existing 
implementation within nations and localities.
Here, we describe a subsequent study to explore the 
perceptions of medicines policymakers of the extent of 
implementation of those 26 consensus-based policy solutions 
within member states of the European Union. Specifically, 
we set out to explore the following:
1) The extent to which each of the 26 consensus-based policy 
solutions had been implemented in European countries.
2) Where countries have implemented one or more of the 
policy solutions, to obtain information on any benefits 
and costs resulting from implementation.
3) Perceptions of the appropriateness of current levels of 
implementation.
4) Where countries have not implemented the policy solu-
tions, to determine whether the recommendations will 
feature in future planning to address nonadherence to 
medication.
5) Any perceived barriers to implementing the policy solu-
tions within countries.
Method
Participants
Purposive sampling was used to identify the National Lead 
with responsibility for medicines policy, including adherence 
to medication, in each of the (then) 27 member states of the 
European Union. National Leads were contacted through 
correspondence with National Ministries of Health, National 
Medicines Authorities or Agencies, and representatives of 
the European Medicines Agency. National Leads who were 
unable to take part in the study were invited to nominate 
their deputies to participate (all participants are referred to 
as National Leads here). During the process of sampling, it 
became apparent that responsibility for policy on adherence 
was often distributed across various individuals, departments, 
and even authorities. In these cases, National Leads were 
invited to refer questions to colleagues if they did not feel 
well-placed to respond. All components of the study were 
conducted in the English language.
Design
A mixed-methods design was employed. A cross-sectional 
online survey was administered through Survey Monkey 
software in the first phase of the study, and semi-structured 
telephone interviews were conducted in the second phase.
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Measures
self-assessment survey
The self-assessment survey was designed to enable quantita-
tive assessment of each country’s own policies on medication 
adherence in relation to the 26 consensus-based adherence 
policy solutions. Policy solutions were presented in the fol-
lowing categories, according to the main target of action: 
patient-focused, health care professional-focused, clinician–
patient interaction-focused, health-system-focused, and 
government-focused solutions as shown in Table 1.
Participants were asked to rate each policy solution 
on two scales. The first scale assessed the extent to which 
each policy solution had been implemented in the respon-
dent’s nation, using a five-point Likert-type response scale 
anchored by “discussed and considered but not implemented” 
(1) and “fully implemented in all regions for all health 
conditions” (5). The second scale measured participants’ 
perceptions of appropriateness of the level of implementation 
for each policy solution. Ratings were made on a five-point 
Likert-type response scale anchored by “far too little imple-
mentation” (1) and “far too much implementation” (5). These 
scales were adapted from the medication self-assessment 
scale of the Institute for Safe Medication Practices.10
interview schedule
The interview schedule was developed to explore partici-
pants’ responses to the self-assessment survey and to identify 
examples of best practice for adherence to medication in 
each of the countries. A semi-structured approach was taken 
to ensure a degree of standardization across the interviews 
while also allowing participants to raise other issues, ideas, 
or concerns.11 Questions focused on eliciting examples of 
Table 1 The european consensus-based policy solutions for medicines adherence
Patient-focused solutions
 1 Provide patients with support, education, and information when a medication is newly prescribed
 2 Provide patients with support, education, and information focused on the patients’ treatment
  3  Provide patients with support, education, and information about the benefits of adherence to their particular medication(s)
 4 Provide patients with support, education, and information about potential side effects or adverse effects and how to manage them
  5  Provide patients with support, education, and information to assist them to weigh up the benefit and harm of medication
 6 Provide patients with support, education, and information tailored to their individual preferences or needs
Health care professional-focused solutions
 7 health care professionals should receive education and training about patient-centered care
 8 health care professionals should receive education and training about identifying and assessing medication nonadherence
  9  Health care professionals should receive education and training about ways of addressing medication nonadherence when it is identified
10 health care professionals should adopt a nonjudgmental approach to the issue of medication adherence
11 health care professionals should identify medication nonadherence
12 health care professionals should provide patients with ongoing feedback and support with medication-taking
13 health care professionals should support patients with concerns about, or experience of, side effects of medication
14  Health care professionals should make sufficient time for the patient, for instance, through more frequent, timely contact
Health care professional–patient interaction-focused solutions
15 Together, health care professionals and patients should discuss the patients’ preferences for treatment
16 Together, health care professionals and patients should ensure a partnership approach in decision-making and treatment
17 Together, health care professionals and patients should discuss the patients’ health- and medication-related beliefs
18 Together, health care professionals and patients should build the patients’ trust in the health care professional
Medication-focused solutions
19  Regarding medicines, simplify the patients’ medication regimen as appropriate (eg, less frequent, modified formulation and/or dosage, tailored to 
individual need)
20  Regarding medicines, stop medication(s) that the patient no longer needs or wants
Health care systems solutions
21 health care providers should promote a team approach, sharing information to deliver consistent adherence support
22 health care providers should prioritize medication adherence support in service, organization, and systems design
Government/payer-focused solutions
23  Governments/health care payers should increase public awareness of medication adherence for all citizens
24  Governments/health care payers should develop and implement evidence-based interventions for medication adherence
25  Governments/health care payers should provide training and guidance for all health care providers so they can deliver effective adherence 
interventions
26  Governments/health care payers should invest in research to identify effective interventions demonstrating value for money
Note: © 2012 clyne et al.; licensee BioMed central ltd. Adapted from clyne W, White s, Mclachlan s. Developing consensus-Based Policy solutions for Medicines 
Adherence for europe: a Delphi study. london: BMC Health Services Research; 2012. creative commons license and disclaimer available from: http://creativecommons.org/
licenses/by/4.0/legalcode
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activities to support adherence within the various categories, 
participants’ decision-making processes regarding imple-
mentation of particular policies, barriers to implementation, 
consequences of implementation, and future planning for 
medication adherence. Each participant was also asked about 
models of best practice for supporting adherence within their 
nation. Although a number of key questions were posed to 
each National Lead, for instance, regarding models of best 
practice for medication adherence, the interview schedule 
was tailored to each participant according to their survey 
responses. For instance, if a National Lead had indicated that 
a particular policy solution had been implemented within 
their country, a question on the benefits of implementation 
was incorporated within the interview schedule. Interviews 
proceeded systematically, addressing each category of policy 
solution in turn before moving to more general questions 
about best practices for medication adherence and impres-
sions of the consensus-based policy solutions.
Procedure
Ethical approval for the study was secured from Keele 
University Ethical Review panel. National Leads were invited 
to participate in the study through email correspondence 
during early 2012. Each National Lead received a letter of 
invitation, a participant information sheet, a letter of sup-
port for the study from the Chief Pharmaceutical Officer of 
England, and a briefing document detailing the methods and 
results of the Delphi study. Prospective participants were 
invited to contact the researchers with any queries about 
the study or if they required any further information. All 
participants were informed that their anonymity could not be 
guaranteed because of the specificity of the sample. Partici-
pants were assured that they would be offered the opportunity 
to view drafts of any manuscripts containing their data and 
request amendments. Upon entering the survey, participants 
responded to three informed consent questions regarding their 
participation in the survey. Participants were also asked to 
indicate their consent to take part in a follow-up interview. 
Those who consented to engage in a follow-up interview were 
asked a series of questions about the recording of their inter-
view and the use of quotations from interview transcripts.
Following the provision of consent, participants were pre-
sented with instructions for completing the self-assessment 
survey and proceeded to rate each policy solution. After 
completion of the survey, participants received a feedback 
document containing details of their ratings. Those who 
had consented to engage in a follow-up interview received 
a copy of the interview schedule and were asked to indicate 
their availability for interview. Where possible, interviews 
were conducted within 2 weeks of participants completing 
the survey. All interviews were conducted by two research-
ers over the telephone and lasted between 20 minutes and 
1 hour. Six National Leads consented to the recording of 
their interviews, and one gave permission for detailed notes 
to be taken.
Data analysis
self-assessment survey data
The quantitative data gathered through the survey were col-
lapsed across categories of policy solution. Mean substitu-
tion was used to replace missing data. Summary descriptive 
data were produced for each category of policy solution in 
each country in order to draw cross-country comparisons 
on level of implementation and perceived appropriateness 
of implementation.
interview data
The qualitative data comprised interview transcripts and 
detailed field notes. Each transcript or set of field notes 
was summarized and sent electronically to the appropriate 
National Lead. National Leads were asked to check that the 
summary provided an accurate reflection of the interview 
discussion and invited to add to or amend the content. The 
finalized and approved interview summaries were used as 
the basis for data analysis. Data analysis proceeded in an 
inductive and iterative fashion. Following the approach of 
Lavis et al,12 themes were identified using the constant com-
parative method of analysis. The researchers read interview 
transcripts as they became available and met regularly to 
discuss themes and issues arising from the data. A two-stage 
fragmenting and connecting procedure13 was employed dur-
ing analysis. Initially, individual themes were extracted from 
the data. These themes were then compared both within and 
across interviews to explore the similarities and differences 
in services and provision between countries. In addition to 
facilitating comparisons between countries, this approach 
enabled modification of the interview schedule in light of 
new themes and ideas arising from the data.
Results
Of the 27 National Leads invited to participate in the study, 
ten (Bulgaria, Denmark, Estonia, Finland, Germany, Ireland, 
Latvia, Lithuania, Malta, and the Netherlands) completed 
the self-assessment survey and seven (Estonia, Finland, 
Germany, Ireland, Lithuania, Malta, and the Netherlands) 
engaged in a follow-up interview.
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survey data
The mean total implementation rating for the 26 policy 
solutions across the ten participating countries was 77.97 
(SD =10.38; range =26–130). Bulgaria attained the highest 
overall level of self-assessed implementation, and Estonia 
provided the lowest total implementation rating (Figure 1). 
The mean implementation scores across countries for each 
category of policy solution (Figure 2) indicated that most 
implementation had taken place at the patient level including, 
for example, the provision of support, education and infor-
mation about newly prescribed medicines, and the benefits 
of adherence. This was followed closely by activity focused 
on improving patient–clinician interactions, for instance, 
through the implementation of a partnership approach. The 
lowest amount of activity was reported for policy solutions 
at the government or health care payer level, which included 
investment in research to identify effective interventions 
demonstrating value for money and increasing public aware-
ness of medication adherence. For all six categories of policy 
solutions, the mean rating for perceived appropriateness of 
level of implementation fell ,3.00, indicating that across 
the ten European countries in the survey, National Leads felt 
insufficient implementation had taken place for medication 
adherence in all policy areas.
The mean level of implementation and perceived appro-
priateness of implementation for each category of policy 
solution are shown for each of the ten countries in Figure 3. 
The mean ratings of perceived appropriateness of imple-
mentation are below the midpoint for 52 of the 60 scores, 
suggesting that the majority of National Leads felt that more 
could or should be done to support patients with adherence 
to medication within their nations, across target areas.
interview data
A range of themes around medication adherence emerged 
from the interview data, and the majority of themes were 
present across the data of two or more interviewees. Out-
lines of these themes are presented below. Key differences 
between nations with high and low levels of implementation 
activity are shown in Figure 4.
responsibility for medicines adherence policy and 
planning: meta level
Four nations (Finland, Germany, Malta, and the Netherlands) 
described shared responsibility for adherence policy and 
planning at the higher level. The particular parties involved 
differed between the nations. Within the Netherlands, for 
example, the role of the government was described as a sys-
tems approach: ensuring good openings for adherence within 
the health system and removing obstacles. The policy lead 
in this nation explained that activity was implemented on a 
regional basis, as solutions were differentially effective in 
different regions. Health care insurers were portrayed as well 
placed, to influence the behavior of health care providers and 
patients with regard to adherence. An official working group 
for adherence, consisting of doctors, nurses, pharmacists, 
patients, insurers, and researchers, was seen as integral to 
adherence implementation in the Netherlands.
Figure 1 Total policy implementation score for each country.
Notes: Minimum possible score =26; maximum possible score =130.
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Absence of adherence “theme” in policy documents 
and practice
Six interviewees emphasized the “hidden” nature of adher-
ence in both policy and practice. Several interviewees stated 
that policy documents in their nations did make reference to 
adherence, but these references were often distributed among 
a number of other topics, such as patient safety, rather than 
falling under the discrete label of “medication adherence”. 
This reduced the visibility of medicines adherence as a focus 
in policy activity. Two of the policy leads indicated that the 
area of medication adherence was overshadowed by more 
pressing issues, such as the availability of medicines, or 
subject to competition for funding from other medicines-
related topics.
The policy lead for adherence in the Netherlands 
explained that the decision to invest in services for adherence 
had been simple and cited the World Health Organization’s1 
report on adherence to long-term therapies as a prompt.
It was really quite simple because there was this WHO 
report about adherence … and it said that about 50% of 
chronically ill patients didn’t use their medicines as they 
were supposed to be used and when you see how much we 
pay for medicines in the healthcare system and then you 
say well, we throw away 50% of this; that’s quite a sum! 
… Yes, and that’s really what made the case here to have 
investments in this area. And we still invest in this area, 
but on a nationwide scale, not a regional or local one. [the 
Netherlands, 97–107]
In two other countries, the case for investment was less 
straightforward. Interviewees in Estonia and Germany indi-
cated that a lack of money and resources presented significant 
barriers to implementing initiatives for adherence, even when 
strong proposals were in place.
evaluating options and assessing outcomes
Three interviewees described difficulties in deciding which 
particular initiatives to implement. The policy lead for the 
Netherlands stated that some initiatives have clearly deserved 
government support, while decisions for other initiatives 
were less clear-cut. Issues relevant to these decisions included 
the scope of expected benefit in terms of widespread or local-
ized effect, the expense of the initiative, and support from 
doctors or pharmacists. Interviewees in Estonia and Finland 
emphasized the need for research to identify effective and 
cost-effective interventions.
Interviewees for Finland, Germany, Ireland, Lithuania, 
and the Netherlands outlined the complexities of evaluating 
outcomes or benefits of initiatives for adherence. Specific 
problems included establishing objective, relevant, and 
independent assessment methods. Barriers to evaluation 
were discussed, such as shortages in time, resources, skills, 
and other competing priorities. A lack of studies evaluating 
the outcomes of initiatives was also raised as a problem. The 
policy lead for Finland highlighted the difficulty involved 
with identifying improvements in medication adherence, 
particularly as improvements in health outcomes cannot 
necessarily be attributed to increased adherence.
Variability in provision and the targeting of resources
Policy leads in Finland, Lithuania, and Malta described vari-
ability, both planned and unplanned, in provision for medica-
tion adherence across different areas of practice and patient 
groups. In Finland, adherence was reported to be addressed 
more thoroughly in patients with long-term conditions, such 
as cardiac disease, diabetes, and asthma, as these patients 
tend to meet with their doctors more frequently than other 
patients. The policy lead for adherence in Malta contrasted 
areas of excellence, for instance, specialist teams where there 
Figure 4 comparison of an exemplar nation with more activity for adherence with exemplar of nation with less activity.
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is good communication between health care professionals 
and patients, strong collaboration between various health 
care professions, and detailed information available on the 
patient’s history, with the general system, in which time and 
support for the patient are more limited.
Interviewees in Finland, Ireland, Malta, and the 
Netherlands referred to the targeting of resources and ser-
vices. One strategy for targeted adherence support was a 
focus on patient groups with the more prevalent long-term 
conditions, for example, diabetes and asthma. Targeted sup-
port for adherence in the Netherlands focused particularly on 
conditions where medicines adherence can be more difficult, 
such as schizophrenia and asthma. Interviewees in Ireland 
and Malta reported the targeting of some initiatives, for 
example, medication review in Ireland, to particular clinical 
areas or to patients on complex regimes and/or with comor-
bidities. The targeting of services toward patients prescribed 
certain medicines, such as those needing regular monitoring, 
was also detailed by the policy lead for Malta.
Barriers to implementation
Interviewees mentioned a number of barriers to the imple-
mentation of policy solutions for medication adherence. 
Some of these barriers were common to several countries. 
A lack of resources and difficulty with financing activity for 
adherence were reported for Estonia, Finland, and Ireland. 
The need to ensure acceptance of the policy solutions and 
openness to patient-centered approaches were mentioned by 
interviewees for Estonia and Malta. Other barriers to imple-
mentation included delay and procrastination, shortages in 
doctors and health care centers, the difficulty of implementing 
best practice developed in one region into another region, 
and a lack of awareness in the general public with regard to 
aspects of medicines use. The challenge of achieving a bal-
ance between enforcement of policy and practicable imple-
mentation was described by the policy lead for Malta.
The impact of major health system changes on 
adherence
Three interviewees described the indirect effects of broad, 
health system reforms on implementation of medicines 
adherence initiatives. Major changes to the health care 
systems over recent years were described for each of these 
countries. Reforms in the Netherlands included increasing 
the role of health care insurers in designing pharmaceuti-
cal care. A radical overhaul of the health care system was 
reported for Ireland, and effects were described as filtering 
down to impact a variety of domains, including adherence. 
Reforms in this nation also affected regulatory bodies and 
the education and training of health care professionals. The 
policy lead in Malta indicated that organizational changes 
offered a good opportunity to implement new standards for 
the use of medicines. The policy lead for Ireland referred to 
European Union initiatives, such as requirements for patient 
information, which may positively impact support for adher-
ence in individual nations.
responsibility for adherence – patient level
Consistent with interviewees’ comments regarding respon-
sibility and planning at the higher level, responsibility for 
adherence-focused activity at the patient level was also 
reported as shared across a number of stakeholders. The 
policy lead in the Netherlands emphasized the responsibility 
of “the triangle” – doctors, pharmacists, and patients – in 
making progress on adherence. Interviewees in Finland, 
Germany, Ireland, Lithuania, and Malta also referred to 
obligations on doctors and pharmacists to produce and deliver 
patient information, not restricted to but including that on 
adherence. The involvement of patient organizations in the 
provision of patient information was outlined by the policy 
leads for Estonia, Finland, Germany, and Malta, while the 
leads for Estonia and Finland additionally acknowledged 
the role played by the pharmaceutical industry in funding 
or collaborating with patient organizations. The policy lead 
for Finland also mentioned the importance of expert nurses 
in assisting patients with adherence to medication.
health care professionals’ training and education
Policy leads in Finland, Ireland, and Malta indicated that 
training and education on adherence to medication in their 
nations were especially well developed for pharmacists. 
In addition to content on adherence within the curricula of 
pharmacy courses, the National Lead for Malta explained 
that adherence is also covered within voluntary continuing 
professional education offered by the College of Pharmacy 
Practice. The interviewee in Ireland described a heavy 
emphasis on medication adherence in the training of pharma-
cists, particularly with regard to antibiotics, antidepressants, 
and antirejection therapy. Finland’s policy lead reported a 
drive toward campaigns to educate pharmacists on how to 
improve medication adherence.
The policy leads in Germany, Ireland, and Malta all 
referred to the role of continuing professional development in 
education and training on adherence. Practice learning under 
the supervision of a tutor was also mentioned as occurring 
within Ireland. The interviewees in Germany and Ireland, 
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as well as Lithuania, discussed health care professionals’ 
training in methods that may promote adherence, such as 
patient-centered care and developing a partnership approach 
with patients. Interviewees also outlined some recent 
advances in training and education on adherence, such as doc-
tors and nurses taking more credits on aspects of medicines 
use in Malta and the development of educational programs 
for doctors in Lithuania. The policy lead in Estonia stated 
that no research had been conducted on support for health 
care professionals in addressing patients’ nonadherence, so 
the extent to which this support is provided was unknown.
Partnership approach
A partnership approach between patients and health care pro-
fessionals was reported as implicit within the health systems 
of three countries: Germany, Ireland, and Malta. Policy leads 
in these countries indicated that health care professionals 
are aware of the importance of implementing a partnership 
approach. The interviewee for Germany commented that 
doctors and pharmacists may not explicitly discuss the need 
for a partnership approach with patients, but are nonetheless 
aware of the need to use such an approach.
Interviewees representing Ireland and Malta suggested 
that the health system culture in their nations now served to 
promote a partnership approach with patients, through the 
transition from a more paternalistic situation to one in which 
patients are able to participate more actively in decisions 
about their medicines.
interprofession collaboration
Collaboration between professions in addressing patients’ 
nonadherence was reported to varying degrees in Germany, 
Ireland, and the Netherlands. While the policy lead in the 
Netherlands described an established system of collabora-
tion between pharmacists and doctors at the state level to 
ensure that information provided to patients is consistent, 
the policy lead in Germany mentioned proposed activities 
for improving the coworking between pharmacists and doc-
tors within an action plan for drug safety. This interviewee 
acknowledged the need to improve cooperation, not only 
from the perspective of drug safety but also in a more general 
way. The policy lead for Ireland stated that steps had been 
taken toward promoting a collaborative approach between 
health care professions. For instance, the Health Service in 
Ireland pays pharmacists a nondispensing fee for medication 
prescribed but not dispensed, as an incentive to encourage 
collaboration between medical practitioners and pharmacists 
about the appropriateness of medicines.
The role of technology in adherence
Policy leads in Ireland, Lithuania, Malta, and the Netherlands 
described the abundance of objective information about medi-
cines on the internet, including summaries of product charac-
teristics and patient information leaflets. However, the use of 
this information by patients was unknown. The interviewee for 
the Netherlands explained that technology was being utilized to 
develop a nationwide monitor on adherence to assess whether 
initiatives to increase adherence have resulted in improved use 
of medicines. This monitor will allow comparisons to be made 
between different diseases and regions. Electronic systems to 
collate and share information on dispensing of prescriptions 
were discussed by the interviewees for Estonia and Lithuania. 
A digital system containing histories of patients’ medicines 
is used by general practitioners to infer patients’ adherence in 
Estonia, while an electronic prescribing system is under devel-
opment in Lithuania. The policy lead in Ireland stressed the 
importance of health information technology in facilitating the 
sharing of information to deliver consistent adherence support, 
increasing public awareness of adherence, and enabling health 
care professionals to spend more time with patients. Such 
technology was described as having the potential to improve 
practice and produce a more cost-efficient health system.
Advice for other nations
With regard to advice for other nations, cooperation between 
stakeholders was described as particularly important. The 
interviewees for Finland, Malta, and the Netherlands referred 
to the need to engage all parties, such as patients, pharmacists, 
doctors, and government, in the planning and implementation 
of activity for adherence. Other recommendations offered by 
these countries included recognizing adherence as a problem 
to be addressed, striving for national-level coordination in 
initiating activity, and using clear treatment guidelines to 
facilitate standardization. The policy lead for Malta also 
suggested the targeting of interventions to those areas that 
would result in the greatest benefit, both financially and in 
terms of patient outcomes.
comprehensiveness of the policy solutions
Six interviewees were asked about the comprehensiveness of 
the policy solutions, and all felt that they provided a complete 
account of the activity needed to address nonadherence. None 
of the interviewees suggested additional solutions.
Discussion
European medicines policy leads differ in their percep-
tions of the extent to which policies to support medication 
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adherence have been implemented in their own countries. 
Policy leads reported that more implementation had taken 
place for solutions at the patient, patient–clinician interac-
tion, and medicine levels than solutions at government or 
health care payer levels of action. In general, across the ten 
countries, implementation of medication adherence policy 
solutions was perceived to be insufficient. Medicines policy 
leads noted that medication adherence has limited visibility 
within policy documents, can be overshadowed by other 
health policy issues, and that difficulty demonstrating impact 
makes it harder to make a case for investment in adherence 
support. Countries with more successful implementation have 
a number of characteristics: coordinated multi-stakeholder 
forums, national-level support and drive, and a patient-
centered approach to health care.
This is the first study we are aware of to examine the 
extent of implementation of medication adherence policy 
solutions and to do so across a number of countries. Though 
the sample size is lower than desired, it includes medicines 
policy leads from Western, Central, and Eastern Europe 
and from Northern and Southern Europe. In the absence 
of  medication adherence outcome indicators, or bench-
marks for medication adherence support, key informant 
interviews with medicines policy leads are an effective 
method for exploring the factors that influence how options 
for medication adherence implementation are formulated and 
the factors that determine the nature and level of implementa-
tion. Furthermore, as the subjective beliefs and opinions of 
policymakers are likely to impact on policy decisions and the 
allocation of resources,14 the ways in which policymakers per-
ceive and understand the nature of medication nonadherence 
and the potential policy options for supporting medication 
adherence are of clear interest.
Social desirability bias to the survey may have led respon-
dents to report more medication adherence implementation 
than is actually the case, to give a favorable impression of 
health service provision in their country. Several factors 
should be taken into account here. First, all respondents were 
potentially exposed to social desirability bias, yet varying 
perceptions of the level of implementation were reported. 
Seven of the ten respondents participated in follow-up inter-
views, and responses to the survey were discussed in detail. 
Participants would likely have encountered difficulty discuss-
ing and exploring their survey responses during interview 
if those responses were fallacious. Also, many respondents 
reported that the implementation of specific policy solutions 
was insufficient, an unlikely response if participants were 
weighted by a heavy social desirability bias.
The medicines policy leads described the implementation 
of medication adherence policy, in general, to be less than 
ideal and described a number of factors that impede them 
from formulating and implementing policy solutions in 
this area. Given the multidimensional nature of medication 
adherence and the way in which responsibility for medica-
tion adherence cuts across health care professional groups 
and sectors, and indeed across departments and roles in 
Ministries of Health, the low level of action reported at the 
systems and government levels is a concern. Examples of 
action at these levels were reported by a minority of nations, 
for example, the use of multi-stakeholder national forums 
and a policy drive to address medication adherence, and 
serve as models for other countries struggling to implement 
policy solutions in this area. The need to raise the profile of 
medication adherence in health policy formulation, reported 
to be hidden or invisible in policy documentation in many 
countries, also emerges as a priority for the medication 
adherence community.
In the majority of countries surveyed, activity to enhance 
or support medication adherence was rarely described as 
coordinated or part of a larger strategic policy program but 
seemed instead to emerge in a more ad hoc fashion and be 
focused at interventions aimed at modifying or supporting 
individual patient behavior. When activity was planned, 
it was also often targeted. Two main targeting strategies 
emerged: a focus on high prevalence long-term conditions, 
such as diabetes and asthma, and a focus on patients pre-
scribed medicines with an element of complexity such as a 
requirement for additional monitoring for safety purposes or 
medicines that are known to be more problematic. The rela-
tive efficacy of these two strategies for enhancing medication 
adherence is unknown.
Several factors mentioned by the medicine leads hin-
der productive policymaking in this area and are also less 
amenable to rapid change. The medicines policy leads were 
short of evidence for the clinical and cost-effectiveness of 
intervening to address medication adherence, making it dif-
ficult for them to build a strong case for investment. Only 
one country – the Netherlands – reported that the prima facie 
evidence of the size of the problem of medication adherence 
and the implicit consequences of nonadherence for morbid-
ity and mortality were sufficient in themselves to stimulate 
government-level action. In the medium to long term, it 
would seem likely that convincing evidence of the cost and 
clinical benefits of medication adherence support, well com-
municated to policymakers, will be necessary to stimulate 
concerted action to address medication adherence.
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Conclusion
This study used medicines policy leads from a number of Euro-
pean countries as key informants to understand the selection, 
implementation, and barriers to implementation of policies 
addressing medication adherence. National policy leads felt 
insufficient implementation of medication adherence policy 
solutions had taken place in all potential target areas. We dem-
onstrate that while European countries differ in some key ways, 
such as the extent to which patient-centered care is dominant 
in health care culture and the existence of structured policy 
forums for medication adherence, medicines policy leads 
experienced similar difficulties and challenges in implementing 
medication adherence policy solutions and shared similarities 
in the nature of successful implementation. This suggests that 
coordinated action between countries at European level and 
the sharing of good practice in medication adherence policy 
formulation and policy implementation may be beneficial.
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